CTOs on the Move

Havas Health

www.havashealth.com

 
Havas Health houses Havas Life (formerly known as Euro RSCG Life), Health4brands (H4B), and Havas Lynx, three wholly-owned Health and Communications Networks, and defines policies and processes for the entire group. Its customer-centric approach has the talent, tenacity and technology that companies, brands and people need to thrive in today`s world.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

TriRivers Health Partners

TriRivers Health Partners is a Rockford, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Healthcare Dist Solutions

Healthcare Dist Solutions is a Lawrence, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vial

Vial is a leading clinical trial site network that runs highly efficient clinical trials. Vial operates a network of clinical trial research sites within Dermatology clinics across the country. Vials clinical trial recruiting engine, software and oper...

Project House

Project House is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.